FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Traistaru Elena 2. Issuer Name and Ticker or Trading Symbol Emerald Bioscience, Inc. [ EMBI ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
CFO and Secretary
(Last)         (First)         (Middle)
5910 PACIFIC CENTER BOULEVARD, SUITE 320
3. Date of Earliest Transaction (MM/DD/YYYY)
8/7/2020
(Street)
SAN DIEGO, CA 92121
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Consultant Option Grant (Right to Buy)  $0.045  8/7/2020    A     1000000       (1) 8/7/2030  Common Stock  1000000  $0  1000000  D   

Explanation of Responses:
(1)  Each of the Options shall be exercisable for a price of $0.045 per Option Share for ten years from August 7, 2020 (the "Grant Date") and all Options will vest 10% on the Grant Date and 90% in equal semiannual installments over four years.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Traistaru Elena
5910 PACIFIC CENTER BOULEVARD
SUITE 320
SAN DIEGO, CA 92121


CFO and Secretary

Signatures
/s/ Elena Traistaru 8/11/2020
**Signature of Reporting Person Date
Emerald Bioscience (QB) (USOTC:EMBI)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more Emerald Bioscience (QB) Charts.
Emerald Bioscience (QB) (USOTC:EMBI)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more Emerald Bioscience (QB) Charts.